Provided by Tiger Trade Technology Pte. Ltd.

Cellectar Biosciences

1.78
-0.0900-4.81%
Post-market: 1.820.0400+2.25%19:30 EDT
Volume:48.04K
Turnover:88.33K
Market Cap:16.82M
PE:-0.81
High:1.98
Open:1.95
Low:1.78
Close:1.87
52wk High:6.52
52wk Low:1.78
Shares:9.45M
Float Shares:9.01M
Volume Ratio:0.63
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2100
EPS(LYR):-8.3544
ROE:-119.57%
ROA:-58.44%
PB:0.56
PE(LYR):-0.21

Loading ...

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

GlobeNewswire
·
Jul 15

Cellectar Biosciences initiated with a Buy at Brookline

TIPRANKS
·
Jul 13

Cellectar Biosciences Shareholders Approve Key Governance Measures

TIPRANKS
·
Jul 11

Cellectar Biosciences Shareholders Approve 2 Million-share Increase to 2021 Stock Incentive Plan

Reuters
·
Jul 11

Cellectar BioSciences director Andrew Gu files initial beneficial ownership statement

Reuters
·
Jun 10

Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia

Reuters
·
Jun 02

Cellectar says iopofosine I-131 posts 79.2% major response rate in Phase 2 CLOVER-WaM subgroup after BTK inhibitors

Reuters
·
Jun 01

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire
·
Jun 01

Cellectar Biosciences Bets on Iopofosine Breakthrough

TIPRANKS
·
May 20

Cellectar Biosciences Files for Secondary Offering of Common Shares

MT Newswires Live
·
May 20

Cellectar Biosciences files to sell 51.21M shares of common stock for holders

TIPRANKS
·
May 20

Cellectar Biosciences Inc - Files for Offering of up to 51.2 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
May 20

Cellectar Biosciences Announces Board Changes and New Director

TIPRANKS
·
May 19

Cellectar BioSciences announces annual shareholder meeting notice

Reuters
·
May 19

Cellectar Biosciences appoints Nantahala analyst Andrew Gu to board

Reuters
·
May 19

Cellectar Biosciences Coverage Assumed by Ladenburg Thalmann at Buy

Dow Jones
·
May 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 15

Cellectar Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Cellectar Biosciences Q1 net loss narrows, completes $140 mln financing

Reuters
·
May 14

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

THOMSON REUTERS
·
May 14